These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 36738973)

  • 1. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.
    Yang L; Hao Y; Boeckmans J; Rodrigues RM; He Y
    Pharmacol Ther; 2023 Mar; 243():108353. PubMed ID: 36738973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.
    Jiang F; Chen Q; Wang W; Ling Y; Yan Y; Xia P
    J Hepatol; 2020 Jan; 72(1):156-166. PubMed ID: 31568800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
    Villard A; Boursier J; Andriantsitohaina R
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages.
    Liu H; Niu Q; Wang T; Dong H; Bian C
    Int J Biol Sci; 2021; 17(14):3745-3759. PubMed ID: 35261562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological mechanisms and therapeutic targets of fatty liver diseases.
    Wang H; Mehal W; Nagy LE; Rotman Y
    Cell Mol Immunol; 2021 Jan; 18(1):73-91. PubMed ID: 33268887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis.
    He Y; Rodrigues RM; Wang X; Seo W; Ma J; Hwang S; Fu Y; Trojnár E; Mátyás C; Zhao S; Ren R; Feng D; Pacher P; Kunos G; Gao B
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33301423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH).
    Qi X; Lai J
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Vesicles as Inflammatory Drivers in NAFLD.
    Srinivas AN; Suresh D; Santhekadur PK; Suvarna D; Kumar DP
    Front Immunol; 2020; 11():627424. PubMed ID: 33603757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
    Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Hwang S; Yun H; Moon S; Cho YE; Gao B
    Front Endocrinol (Lausanne); 2021; 12():751802. PubMed ID: 34707573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of extracellular vesicles in nonalcoholic fatty liver disease.
    Jiang W; Xu Y; Chen JC; Lee YH; Hu Y; Liu CH; Chen E; Tang H; Zhang H; Wu D
    Front Endocrinol (Lausanne); 2023; 14():1196831. PubMed ID: 37534206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.
    Hirsova P; Ibrahim SH; Krishnan A; Verma VK; Bronk SF; Werneburg NW; Charlton MR; Shah VH; Malhi H; Gores GJ
    Gastroenterology; 2016 Apr; 150(4):956-67. PubMed ID: 26764184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Options and Future Directions for NAFLD and NASH Treatment.
    Zhang C; Yang M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on the Chemokine System in the Development of NAFLD.
    Nagata N; Chen G; Xu L; Ando H
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
    Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.